Retatrutide and MOTS-c Research Updates

What is Retatrutide?

Retatrutide (investigated under NCT05929066) is a novel triple receptor agonist that targets the GLP-1, GIP, and glucagon pathways. This "tri-agonist" approach is currently being evaluated for metabolic research endpoints and receptor-signaling questions.

In clinical research published in the New England Journal of Medicine (NEJM), researchers reported changes across metabolic endpoints. Research readers should review trial design, population, endpoints, and sponsor context before treating headline percentages as standalone evidence.

Understanding MOTS-c

MOTS-c, a mitochondrial-derived peptide, functions as a metabolic signaling molecule. Researchers are evaluating its role in activating the AMPK pathway, which is central to energy homeostasis and glucose metabolism.

Peer-reviewed studies suggest that MOTS-c provides a link between mitochondrial health and systemic metabolic signaling. However, current research into MOTS-c remains in the early/pre-clinical stages.

Research and Compliance

The compounds discussed (Retatrutide and MOTS-c) are investigational and are intended for research purposes only. They have not been approved for human use or therapeutic treatment.

Related research-literacy guides

Want an education-first checklist for reading peptide research claims?

Get the research kit